Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.

@article{Baker2012CosteffectivenessAO,
  title={Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.},
  author={Timothy M. Baker and Jowern Goh and Atholl Johnston and Heather Falvey and Yvonne Brede and Ruth E. Brown},
  journal={Journal of medical economics},
  year={2012},
  volume={15 2},
  pages={
          253-60
        }
}
  • Timothy M. Baker, Jowern Goh, +3 authors Ruth E. Brown
  • Published in Journal of medical economics 2012
  • Medicine
  • OBJECTIVES Losartan will shortly become generic, and this may encourage switching to the generic drug. However, valsartan was shown in a meta-analysis to be statistically superior in lowering blood pressure (BP) to losartan. This paper examines the costs of treatment with these two drugs and the potential consequences of switching established valsartan patients to generic losartan. METHODS A US payer cost-effectiveness model was developed incorporating the risk of cardiovascular disease (CVD… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    References

    Publications referenced by this paper.
    SHOWING 1-3 OF 3 REFERENCES

    Cost - effectiveness analysis of valsartan versus losartan and the effect of switching

    • TM Baker, J Goh, +3 authors RE Brown